Antibody-drug conjugates are coming of age with a remarkable surge in recent times, that has marked a turning point in their development. Notable achievements include the ground-shaking triumph of ENHERTU, eye-popping investments like Pfizer's monumental $43 billion acquisition of Seagen, and the FDA’s greenlight for ELAHERE. These milestones have transformed the ADC landscape, driving increased interest and investment in the field, which now has a preclinical and clinical arena dynamically evolving.
As such, the 14th World ADC London returns next March. This will be the first opportunity in the new year to explore these monumental wins, reflect on ongoing challenges, and collaborate on innovative strategies to supercharge all stages of ADC development.
Nordic Life Science Days 2024 will return to Malmö, Sweden on 18-19 September at Malmömässan located Måsgatan 6, 215 32 Malmö – Sweden.
Copyright © 2024 DON Therapeutics - All Rights Reserved.
DON THERAPEUTICS LTD is not a Registered Investment Advisor, Broker/Dealer, Financial Analyst, Financial Bank, Securities Broker or Financial Planner. The Information on this 1. Company email, 2 Company Site, 3 Company LinkedIn is provided for information purposes only. The Information is not intended to be and does not constitute financial advice or any other advice, is general in nature and not specific to you. Before using the Company’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence. None of the information on our email, website, or LinkedIn is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. The Company is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.
Powered by DON Therapeutics